These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29429842)

  • 1. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Sehouli J; Alfaro V; González-Martín A
    Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With
    Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G
    J Clin Oncol; 2024 May; 42(13):1488-1498. PubMed ID: 38315944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
    Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
    Colombo N
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
    Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
    Colombo N; Gadducci A; Sehouli J; Rulli E; Mäenpää J; Sessa C; Montes A; Ottevanger NB; Berger R; Vergote I; D'Incalci M; Churruca Galaz C; Chekerov R; Nyvang GB; Riniker S; Herbertson R; Fossati R; Barretina-Ginesta MP; Deryal M; Mirza MR; Biagioli E; Iglesias M; Funari G; Romeo M; Tasca G; Pardo B; Tognon G; Rubio-Pérez MJ; DeCensi A; De Giorgi U; Zola P; Benedetti Panici P; Aglietta M; Arcangeli V; Zamagni C; Bologna A; Westermann A; Heinzelmann-Schwarz V; Tsibulak I; Wimberger P; Poveda A;
    Br J Cancer; 2023 Apr; 128(8):1503-1513. PubMed ID: 36759720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
    Boccia SM; Sassu CM; Ergasti R; Vertechy L; Apostol AI; Palluzzi E; Fagotti A; Scambia G; Marchetti C
    Drug Des Devel Ther; 2024; 18():2021-2032. PubMed ID: 38863768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
    Del Campo JM; Muñoz-Couselo E; Diaz de Corcuera I; Oaknin A
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):795-805. PubMed ID: 20553205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
    Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.